Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1a, Randomized, Double-blinded, Placebo-controlled, Single-dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ELX-02 in Healthy Adult Volunteers

Next Previous
X
Search
Trial Profile

Phase 1a, Randomized, Double-blinded, Placebo-controlled, Single-dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ELX-02 in Healthy Adult Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exaluren (Primary) ; Exaluren (Primary)
  • Indications Cystic fibrosis; Cystinosis; Duchenne muscular dystrophy; Inborn genetic disorders; Mucopolysaccharidosis I; Rett syndrome
  • Focus Adverse reactions; First in man
  • Sponsors Eloxx Pharmaceuticals

    • Most Recent Events

    • 08 Mar 2019 According to an Eloxx Pharmaceuticals media release, results from phase 1a single-ascending dose (SAD) study for ELX-02 (NCT02807961 and NCT03292302) have been published in the January 2019 edition of the Journal of Clinical Pharmacology and Drug Development.
    • 08 Nov 2018 According to an Eloxx Pharmaceutical media release, the results have been submitted to a scientific journal for publication.
    • 19 Mar 2018 According to an Eloxx Pharmaceutical media release, results from the completed Phase 1 SAD study (NCT02807961 and NCT03292302) will be included in the planned IND and CTA submissions.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top